Renal Association Clinical Practice Guideline on Anaemia of Chronic Kidney Disease

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2017 Dec 2

PMID 29191165

Citations 110

Authors

Ashraf Mikhail

Christopher Brown

Jennifer Ann Williams

Vinod Mathrani

Rajesh Shrivastava

Jonathan Evans

Hayleigh Isaac

Sunil Bhandari

Affiliations

Soon will be listed here.

Abstract

Anaemia is a commonly diagnosed complication among patients suffering with chronic kidney disease. If left untreated, it may affect patient quality of life. There are several causes for anaemia in this patient population. As the kidney function deteriorates, together with medications and dietary restrictions, patients may develop iron deficiency, resulting in reduction of iron supply to the bone marrow (which is the body organ responsible for the production of different blood elements). Chronic kidney disease patients may not be able to utilise their own body's iron stores effectively and hence, many patients, particularly those receiving haemodialysis, may require additional iron treatment, usually provided by infusion.With further weakening of kidney function, patients with chronic kidney disease may need additional treatment with a substance called erythropoietin which drives the bone marrow to produce its own blood. This substance, which is naturally produced by the kidneys, becomes relatively deficient in patients with chronic kidney disease. Any patients will eventually require treatment with erythropoietin or similar products that are given by injection.Over the last few years, several iron and erythropoietin products have been licensed for treating anaemia in chronic kidney disease patients. In addition, several publications discussed the benefits of each treatment and possible risks associated with long term treatment. The current guidelines provide advice to health care professionals on how to screen chronic kidney disease patients for anaemia, which patients to investigate for other causes of anaemia, when and how to treat patients with different medications, how to ensure safe prescribing of treatment and how to diagnose and manage complications associated with anaemia and the drugs used for its treatment.

Citing Articles

Prognostic nutritional index as an independent risk factor for disease progression in patients with IgA nephropathy.

Wang S, Zhou H, Dong L, Qin W Front Med (Lausanne). 2025; 12:1530312.

PMID: 40070651 PMC: 11893860. DOI: 10.3389/fmed.2025.1530312.

Contribution of vitamin B 6 deficiency to anemia in children on regular hemodialysis.

Atia F, Bazaraa H, Abdelatty Y, Lotfy S, Eryan E BMC Pediatr. 2025; 25(1):64.

PMID: 39871236 PMC: 11771028. DOI: 10.1186/s12887-025-05386-1.

Treatment Inertia and Symptom Burden in Anemia of CKD: Insights from the SATISFY Survey in the Middle East, South Africa, and Türkiye.

Arici M, Al-Ghamdi S, Assounga A, El-Koraie A, McMillan A, Camidge L Int J Nephrol Renovasc Dis. 2025; 18:27-42.

PMID: 39866642 PMC: 11766225. DOI: 10.2147/IJNRD.S474716.

Remote management of anaemia in patients with end-stage kidney disease using a wearable, non-invasive sensor.

Steig A, Miller F, Shreim S, Wilcox J, Sykes C, Whittaker D Clin Kidney J. 2025; 18(1):sfae375.

PMID: 39866299 PMC: 11761439. DOI: 10.1093/ckj/sfae375.

Non-linear relationship between urinary creatinine and diabetic kidney disease: implications for clinical practice.

Cao H, Song L, Wang X, Guan H BMC Nephrol. 2025; 26(1):40.

PMID: 39856665 PMC: 11762113. DOI: 10.1186/s12882-025-03971-1.

References

Vasquez E, Pollak R . Effect of pretransplant erythropoietin therapy on renal allograft outcome. Transplantation. 1996; 62(7):1026-8. DOI: 10.1097/00007890-199610150-00024. View

Moulin B, Ollier J, George F, Purgus R, Roux F, Sampol J . Serum erythropoietin and reticulocyte maturity index after renal transplantation: a prospective longitudinal study. Nephron. 1995; 69(3):259-66. DOI: 10.1159/000188467. View

Spinowitz B, Coyne D, Lok C, Fraticelli M, Azer M, Dalal S . C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol. 2007; 28(2):280-9. DOI: 10.1159/000111115. View

Bhandari S, Turney J, Brownjohn A, Norfolk D . Reticulocyte indices in patients with end stage renal disease on hemodialysis. J Nephrol. 1998; 11(2):78-82. View

Hoen B, Hestin D, Kessler M . EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998; 9(5):869-76. DOI: 10.1681/ASN.V95869. View

Brookhart M, Schneeweiss S, Avorn J, Bradbury B, Liu J, Winkelmayer W . Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA. 2010; 303(9):857-64. DOI: 10.1001/jama.2010.206. View

Casadevall N, Cournoyer D, Marsh J, Messner H, Pallister C, Parker-Williams J . Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol. 2004; 73(6):389-96. DOI: 10.1111/j.1600-0609.2004.00348.x. View

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

Pham P, Peng A, WILKINSON A, Gritsch H, Lassman C, Pham P . Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis. 2000; 36(4):844-50. DOI: 10.1053/ajkd.2000.17690. View

10.

Ioannou G, Spector J, Scott K, Rockey D . Prospective evaluation of a clinical guideline for the diagnosis and management of iron deficiency anemia. Am J Med. 2002; 113(4):281-7. DOI: 10.1016/s0002-9343(02)01226-3. View

11.

Fishbane S, Berns J . Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005; 68(3):1337-43. DOI: 10.1111/j.1523-1755.2005.00532.x. View

12.

Ioannou G, Rockey D, Bryson C, Weiss N . Iron deficiency and gastrointestinal malignancy: a population-based cohort study. Am J Med. 2002; 113(4):276-80. DOI: 10.1016/s0002-9343(02)01214-7. View

13.

Richardson D, Bartlett C, Will E . Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis. 2001; 38(1):109-17. DOI: 10.1053/ajkd.2001.25203. View

14.

Vanrenterghem Y, Barany P, Mann J, Kerr P, Wilson J, Baker N . Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002; 62(6):2167-75. DOI: 10.1046/j.1523-1755.2002.00657.x. View

15.

Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft F . Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis. 1995; 26(2):292-9. DOI: 10.1016/0272-6386(95)90649-5. View

16.

Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T . Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014; 86(4):845-54. DOI: 10.1038/ki.2014.114. View

17.

Besarab A, Kaiser J, Frinak S . A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis. 1999; 34(1):21-8. DOI: 10.1016/s0272-6386(99)70103-4. View

18.

Macdougall I, Tucker B, Thompson J, Tomson C, Baker L, Raine A . A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996; 50(5):1694-9. DOI: 10.1038/ki.1996.487. View

19.

Kalantar-Zadeh K, McAllister C, Lehn R, Lee G, Nissenson A, Kopple J . Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis. 2003; 42(4):761-73. DOI: 10.1016/s0272-6386(03)00915-6. View

20.

Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray S . Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant. 2004; 19(4):898-903. DOI: 10.1093/ndt/gfh021. View